Sino Biopharmaceutical Limited (HKG:1177)
Hong Kong · Delayed Price · Currency is HKD 5.03
-0.03 (-0.59%)
Jul 31, 2026, 4:08 PM HKT
Sino Biopharmaceutical Stock Forecast
Stock Price Forecast
According to 22 analysts polled by S&P Global, Sino Biopharmaceutical stock has a consensus rating of "Strong Buy" and an average price target of $8.13. The average 1-year stock price forecast is 61.63% higher than the current stock price, while the lowest is $5.61 (+11.53%) and the highest is $10.01 (+99.01%).
Price Target: $8.13 (+61.63%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Sino Biopharmaceutical stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 18 | 18 | 17 | 17 | 17 | 16 |
| Buy | 5 | 3 | 3 | 4 | 4 | 4 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 24 | 22 | 21 | 22 | 22 | 21 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Unknown Analyst UOB Kay Hian No rating | UOB Kay Hian | Buy Maintains $7.20 | Buy | Maintains | $7.20 | +43.14% | Jul 25, 2026 |
Unknown Analyst Nomura No rating | Nomura | Buy Maintains $8.26 | Buy | Maintains | $8.26 | +64.21% | Jul 24, 2026 |
Unknown Analyst UBS No rating | UBS | Buy Maintains $11.00 → $7.70 | Buy | Maintains | $11.00 → $7.70 | +53.08% | Jul 24, 2026 |
Unknown Analyst Citi No rating | Citi | Buy Maintains $10.00 | Buy | Maintains | $10.00 | +98.81% | Jul 21, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $7.80 | Buy | Maintains | $7.80 | +55.07% | Jul 13, 2026 |
Financial Forecast
Revenue This Year
36.29B
from 31.83B
Increased by 14.01%
Revenue Next Year
39.19B
from 36.29B
Increased by 7.99%
EPS This Year
0.24
from 0.25
Decreased by -4.26%
EPS Next Year
0.26
from 0.24
Increased by 7.18%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is CNY.